🔗 Share this article

As America undertakes unprecedented adjustments to its immunization guidelines, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on Covid vaccines in the pandemic and has concentrated on possible deaths following COVID-19 immunization in her brief time at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders had intended to unveil sweeping revisions to the pediatric vaccination calendar recently, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of step with many the international standard with little proof for public health gain. The planned update has been delayed until the coming year.

In place of Vinay Prasad, Dr. Høeg is set to address the audience at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon dismantling long-standing immunizations at the FDA.

Høeg has often pushed for discontinuing specific pediatric immunization guidelines in the US to become more in line with the Danish model, a country with comprehensive healthcare and a population approximately the size of Wisconsin’s.

In her initial statements, she has kept her attention on vaccines – usually the responsibility of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Background

The appointee has no obvious track record in pharmaceutical research, regulation or management, which has been standard for past directors of the biologics center. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a clinical trial. She has no expertise in running a major agency. She has no expertise in drug approvals.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the science of medication creation”, commented a former acting FDA commissioner. “Frankly, she lacks the type of experience that prior appointees who led CBER have had.”

The drug center has an immense workload at the FDA, the former commissioner stated.

“The public just zeroes in on the novel medication approvals, but the generic program approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and each of these must be managed,” Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a major management element to the job, which manages over 5,000 personnel. “It’s a enormous management job, if you perform it correctly,” the former official said.

Official Statement and Contentious Policies

Regarding inquiries about Høeg’s fitness for the role and whether this appointment represents more teamwork among FDA leaders on vaccines, a representative said that the “questions stem from incorrect assumptions”.

“Her resume aligns with the responsibilities of her job,” the official explained, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s recently launched priority voucher program, a disputed rapid therapy clearance system that allegedly concerned her former heads. “By what process are these medications being picked for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards less stringent oversight of all drugs, except for vaccines.”

Public Track Record on Vaccines

Concerning vaccines, Høeg has a clearer, if concerning, track record, Howard said. She released a study using unconfirmed public submissions to assess the incidence of myocarditis after COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are riskier than they are.

Included in her “wish list” for the new administration featured altering guidelines for novel immunizations and discontinuing “non-essential” vaccines, she remarked post-election on a online show. At the FDA, Høeg has according to sources proposed excluding adolescent males from getting Covid vaccinations.

“She’s an all-around ideologue who commences with her beliefs and works backwards to fit the evidence in a very deceptive, fraudulent fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|